- Home
- NUV vs HRMY Comparison
NUV vs HRMY Comparison
Compare NUV & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NUV | HRMY |
|---|---|---|
| Founded | 1987 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NUV | HRMY |
|---|---|---|
| Price | $8.99 | $38.83 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $44.11 |
| AVG Volume (30 Days) | 505.3K | ★ 827.7K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 3.96% | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | N/A | ★ 1.84 |
| Revenue | N/A | ★ $868,453,000.00 |
| Revenue This Year | N/A | $19.75 |
| Revenue Next Year | N/A | $12.88 |
| P/E Ratio | ★ N/A | $20.73 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $8.55 | $25.52 |
| 52 Week High | $9.26 | $40.87 |
Technical Indicators
Market Signals| Indicator | NUV | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 39.28 | 59.31 |
| Support Level | $8.97 | $34.87 |
| Resistance Level | $9.15 | $39.24 |
| Average True Range (ATR) | 0.06 | 1.28 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 8.82 | 77.04 |
Price Performance
Historical ComparisonAbout NUV Nuveen Municipal Value Fund Inc.
Nuveen Municipal Value Fund Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is to provide current income exempt from regular federal income tax. The Fund's secondary investment objective is to enhance portfolio value and total return.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.